Search Result

Results for "

coronaviruses inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Casein Kinase (1) Cathepsin (1) DNA Methyltransferase (1) Drug Metabolite (1) Endogenous Metabolite (1) PROTACs (1) SARS-CoV (15) Ser/Thr Protease (1) Virus Protease (5)
By Research Areas:	Cancer (1) Infection (17) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99423

Adintrevimab 1 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

HY-139010

Merafloxacin 1 Publications Verification CI-934	SARS-CoV	Infection
Merafloxacin (CI-934), a fluoroquinolone antibacterial agent, is a selective programmed -1 ribosomal frameshifting (-1 PRF) inhibitor of beta coronaviruses. Merafloxacin exhibits in vitro activity against gram-positive and gram-negative bacteria .

HY-149535

Iscartrelvir WU-04	SARS-CoV	Infection
Iscartrelvir (WU-04) is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. Iscartrelvir has high inhibitory effect on the 3CLpro protein of 6 SARS-CoV-2 variants (Alpha, Beta, Gamma, Delta, Lambda and Omicron) and 2 coronaviruses (SARS-CoV and MERS-CoV) .

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

HY-122668

K22	SARS-CoV	Infection
K22 is an inhibitor of coronavirus RNA synthesis that specifically targets membrane-associated coronavirus RNA synthesis. K22 effectively blocks replication of multiple coronaviruses by inhibiting the critical step of viral replication complex anchoring to host cell membranes to form double-membrane vesicles (DMVs). K22 exhibits broad-spectrum antiviral activity against diverse coronaviruses, including Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Feline Coronavirus (FCoV), Mouse Hepatitis Virus (MHV), and Avian Infectious Bronchitis Virus (IBV) .

HY-172960

SARS-CoV-2 Mpro-IN-44	SARS-CoV Virus Protease	Infection Inflammation/Immunology
SARS-CoV-2 Mpro-IN-44 (Compound 25) is a broad-spectrum coronavirus main protease (Mpro) inhibitor. SARS-CoV-2 Mpro-IN-44 has inhibitory activity against a variety of high-risk coronaviruses (including SARS-CoV-2 and PEDV, etc.) (IC₅₀: < 0.6 μM). SARS-CoV-2 Mpro-IN-44 achieves broad-spectrum inhibition of coronaviruses by enhancing the interaction with the conserved sites of Mpro. SARS-CoV-2 Mpro-IN-44 can be used for anti-coronavirus drug development .

HY-161371

VD5123	Ser/Thr Protease	Cancer
VD5123 is a serine protease inhibitor. VD5123 inhibits TMPRS2, HGFA, matriptase, hepsin with IC₅₀s of 15, 3980, 140, 37 nM respectively. VD5123 can be used for antiviral research, such as SARS-CoV-2 and broad panel of coronaviruses and influenza viruses .

HY-105747A

Guanoxyfen nitrate N-(3-Phenoxypropyl)guanidine nitrate; (3-Phenoxypropyl)guanidine nitrate	Endogenous Metabolite	Infection Neurological Disease
Guanoxyfen (N-(3-Phenoxypropyl)guanidine) nitrate is a compound that exhibits potent inhibitory activity against the serine protease enzyme TMPRSS2, which plays a crucial role in the infectivity of coronaviruses. Guanoxyfen nitrate is also an effective inhibitor of vasoconstrictor responses to sympathetic nerve stimulation.

HY-161789

PROTAC SARS-CoV-2 Mpro degrader-3	PROTACs SARS-CoV Virus Protease	Infection
PROTAC SARS-CoV-2 Mpro degrader-3 (Compound P2) exhibits antiviral activity through the degradation of the main protease (Mpro) of human coronaviruses (HCoVs) (DC₅₀=27 μM). PROTAC SARS-CoV-2 Mpro degrader-3 inhibits the viral replication, with EC₅₀ of 4.6 μM, 4.6 μM, and 0.71 μM, for human coronaviruses HCoV-229E, HCoV-OC43 and SARS-CoV-2, respectively. (Pink: ligand for target protein Mpro ligand 2 (HY-161791); Black: linker (HY-161792); Blue: ligand for E3 ligase (S,R,S)-AHPC (HY-125845)) .

HY-172214

AB-343	SARS-CoV Virus Protease	Infection
AB-343 is a selective covalent inhibitor of SARS-CoV-2 M ^pro, with an IC₅₀ of 8 nM and a K_i of 2.8 nM. AB-343 can effectively inhibit the main proteases of SARS-CoV-2 and many other coronaviruses, and is also active against some resistant variants. AB-343 can be used in the research of treating coronavirus infection-related diseases .

HY-144833

SARS-CoV-2 3CLpro-IN-1	SARS-CoV	Infection
SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a potent inhibitor of SARS-CoV-2 3CL ^pro. 3CL ^pro (main coronaviruses cysteine-protease) has been identified as a promising target for the development of antiviral agents. SARS-CoV-2 3CLpro-IN-1 has the potential for the research of infection diseases .

HY-136149A

Mpro inhibitor N3 hemihydrate	SARS-CoV Virus Protease	Infection
Mpro inhibitor N3 hemihydrate is a potent inhibitor of SARS-CoV-2 Mpro with an EC₅₀ of 16.77 μM for SARS-CoV-2. Mpro inhibitor N3 hemihydrate specifically inhibits Mpro from multiple coronaviruses, including SARS-CoV and MERS-CoV. Mpro inhibitor N3 hemihydrate displays inhibition against HCoV-229E, FIPV, and MHV-A59 with individual IC₅₀ of 4.0 μM, 8.8 μM, and 2.7 μM, respectively .

HY-161342

CTSL/CAPN1-IN-2	Cathepsin SARS-CoV	Infection Inflammation/Immunology
CTSL/CAPN1-IN-2 (Compound 14b) is an orally active inhibitor of both CTSL and CAPN1, with IC₅₀ values of 6.88 nM and 347.6 nM, respectively. CTSL/CAPN1-IN-2 possesses anti-inflammatory properties and favorable pharmacokinetic characteristics. CTSL/CAPN1-IN-2 exhibits broad-spectrum antiviral activity against coronaviruses by blocking viral entry .

HY-174320

SARS-CoV-2-IN-112	SARS-CoV	Infection
SARS-CoV-2-IN-112 (Compound 6f) is an orally active and non-peptidic SARS-CoV-2 main protease inhibitor with an IC₅₀ of 6.48 μM. SARS-CoV-2-IN-11 has potent antiviral activity with low cytotoxicity against WI-38 cells (IC₅₀: 53.81 μM). SARS-CoV-2-IN-112 can be used for coronaviruses COVID-19 research .

HY-172350

WEHI-P8	SARS-CoV	Infection
WEHI-P8 is an orally active inhibitor targeting the papain-like protease (PLpro) of coronaviruses. WEHI-P8 againsts SARS-CoV-2 PLpro with an IC₅₀ value of 12 nM. WEHI-P8 has good cellular activity with a EC₅₀ of 298 nM. WEHI-P8 protects mice from SARS-CoV-2 induced long-term symptoms in lung and brain. WEHI-P8 can be used for post-acute sequelae of COVID-19 study .

HY-174439

Nsp12-IN-2	SARS-CoV Virus Protease Drug Metabolite	Infection
Nsp12-IN-2 (Compound 8), the triphosphate metabolite of 4'-thiouridine (HY-W113081), is a SARS-CoV-2 Nsp12 inhibitor. Nsp12-IN-2 inhibits the RNA-dependent RNA polymerase (RdRp) activity of the SARS-CoV-2 Nsp12-Nsp7-Nsp8 complex, terminates RNA synthesis and also blocks the RNAylation and NMPylation of Nsp9. Nsp12-IN-2 is promising for research of infections caused by SARS-CoV-2, other coronaviruses, and other RNA viruses .

HY-163783

CSNK2-IN-1	Casein Kinase	Infection
CSNK2-IN-1 is a potent and selective CSNK2 inhibitor with IC₅₀ of 1.7 nM and 0.66 nM for CSNK2A1 and CSNK2A2, respectively. CSNK2-IN-1 has antiviral activity against beta-coronaviruses such as SARS-CoV-2 and MHV. CSNK2-IN-1 has good solubility, metabolic stability, and low cytotoxicity, but its plasma concentration in vivo decreases rapidly and is insufficient to achieve pharmacological effects. CSNK2-IN-1 can be used in the research of antiviral drug development .

HY-170524

TDI-015051	SARS-CoV DNA Methyltransferase	Infection
TDI-015051 is an orally active inhibitor for SARS-CoV-2 nonstructural protein 14 (NSP14) with an IC₅₀ ≤0.15 nM. TDI-015051 inhibits SARS-CoV-2 NSP14 in Huh-7.5 cell (EC₅₀=11.4 nM) and in ACE2-TMPRSS2 expressing A549 cell (EC₅₀=64.7 nM). TDI-015051 also inhibits other coronaviruses like α-hCoV-NL63, α-hCoV-229E and β-hCoV-MERS with IC₅₀s of 1.7, 2.6 and 3.6 nM, respectively. TDI-015051 binds to the SAH-stabilized cap binding pocket, inhibits viral RNA methylation and viral replication, and exhibits anti-infectious activity in mouse models .

Cat. No.	Product Name	Target	Research Area

HY-P11012

EK1	SARS-CoV	Infection
EK1 is a peptide-based fusion inhibitor of coronaviruses (CoVs) with broad spectrum inhibition to a number of CoV species. EK1 shows substantially improved pan-CoV fusion inhibitory activity. EK1 potently inhibits SARS-CoV-2. EK1 can form a stable six-helix bundle (6HB) structure with both short α-hCoV and long β-hCoV N-terminal heptad repeats .

Cat. No.	Product Name	Target	Research Area

HY-P99423

Adintrevimab 1 Publications Verification ADG 20	SARS-CoV	Infection
Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.